Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: An in vitro and in vivo study

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1237-1245

  Jurado, Rafael ^a   Lopez Flores, Angelica ^a   Alvarez, Aaron ^a   García López, Patricia ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Antihormonals; Cervical cancer; Cisplatin; Drug synergism; Mifepristone

Indexed keywords

CISPLATIN; MIFEPRISTONE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; GENE EXPRESSION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; HORMONE ANTAGONISTS; HUMANS; MICE; MICE, NUDE; MIFEPRISTONE; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE DISTRIBUTION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70449360366     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000560     Document Type: Article

References (37)

1. Bosch FX: Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex 45: S326-S339, 2003.
2. Lörincz AT: Screening for cervical cancer: new alternatives and research. Salud Publica Mex 45: S376-S387, 2003.
3. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
4. Panici PB, Greggi S, Scambia G, et al: High-dose cisplatin and bleomycin neoadyuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol 41: 212-216, 1991.
5. Fontanelli R, Spatti G, Raspagliesi F, et al: A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol 3: 117-121, 1992.
6. Gandara DR, Perez EA, Wiebe V, et al: Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol 18: 49-55, 1991.
7. De Vincenzo R, Scambia G, Benedetti PP, et al: Modulatory effects of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 68: 340-348, 1996.
8. Drucker L, Stackievicz R, Radnay J, et al: Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures. Anticancer Res 23: 1549-1554, 2003.
9. Tavassoli M, Soltaninia J, Rudnicka J, et al: Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-beta1. Carcinogenesis 23: 1569-1575, 2002.
10. Garcia-Lopez P, Rodriguez-Dorantes M, Perez-Cardenas E, et al: Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines. Cancer Chemother Pharmacol 53: 533-540, 2004.
11. Carmichael J, DeGraff WG, Gazdar AF, et al: Evaluation of tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
12. Chou TC: Drug combination: from laboratory to practice. J Lab Clin Med 132: 6-8, 1998.
13. Lopez-Flores A, Jurado R and Garcia-Lopez P: A high- performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples. J Pharmacol Toxicol Methods 52: 366-372, 2005.
14. Liang Y, Hou M, Kallab AM, et al: Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxy-tamoxifen combination therapy: a role for TGFβ1. Int J Oncol 23: 369-380, 2003.
15. El Etreby MF, Liang Y, Wrenn RW, et al: Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 51: 149-168, 1998.
16. Rose FV and Barnea ER: Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12: 999-1003, 1996.
17. Rocereto TF, Saul HM, Aikins JA Jr, et al: Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 77: 429-432, 2000.
18. Schneider CC, Gibb RK, Taylor DD, et al: Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig 5: 334-338, 1998.
19. El Etreby MF, Liang Y, Johnson MH, et al: Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaPC4-2 prostate cancer models in nude mice. Prostate 42: 99-106, 2000.
20. Li DQ, Wang ZB, Bai J, et al: Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol 10: 2628-2631, 2004.
21. Hähnel R, Martin JD, Masters AM, et al: Estrogen receptors and blood hormone levels in cervical carcinoma and other gynecological tumors. Gynecol Oncol 8: 226-233, 1979.
22. Dvorák Z, Vrzal R, Patrick Maurel, et al: Differential effects of selected natural compounds with anti-inflammatory activity on the glucocorticoid receptor and NF-kappaB in HeLa cells. Chem Biol Interact 159: 117-128, 2006.
23. Lu YS, Lien HC, Yeh PY, et al: Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol 11: 6373-6380, 2005.
24. Gaddy VT, Barrett JT, Delk JN, et al: Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cell. Clin Cancer Res 10: 5215-5225, 2004.
25. Murphy AA, Zhou MH, Malkapuram S, et al: RU486-induced growth inhibition of human endometrial cells. Fertil Steril 74: 1014-1019, 2000.
26. Han S and Sidell N: RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 88: 713-719, 2003.
27. Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-KappaB transcription factors. Oncogene 18: 6910-6924, 1999.
28. Matsushita H, Morishita R, Nata T, et al: Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Cir Res 86: 974-981, 2000.
29. Marino M, Acconcia F, Bresciani F, et al: Distinct non-genomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin (D1) gene transcription in HepG2 cells. Mol Biol Cell 13: 3720-3729, 2002.
30. Horwitz KB: The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13: 146-163, 1992.
31. Yang CP, DePinho SG, Greenberger LM, et al: Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782-788, 1989.
32. Ueda K, Okamura N, Hirai M, et al: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252, 1992.
33. Hait WN and Aftab DT: Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 43: 103-107, 1992.
34. Lecureur V, Fardel O and Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 355: 187-191, 1994.
35. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
36. Qin TN and Wang LL: Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism. Di Yi Jun Yi Da Xue Xue Bao 22: 344-346, 2002.
37. Liu Y, Wang LL and Deng Y: Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo. Di Yi Jun Yi Da Xue Xue Bao 23: 242-244, 2003.